Towards a Self‐Adjuvanting Multivalent B and T cell Epitope Containing Synthetic Glycolipopeptide Cancer Vaccine

Abstract

A new generation of synthetic cancer vaccine: the first self-adjuvanting vaccine prototype combining a cluster of B cell epitope, a CD4+ T helper cell epitope, a CD8+ T cell epitope, and an immunoadjuvant has been synthesized by a chemoselective strategy. Vaccination of mice with this molecularly defined construction induces a strong protection against tumors. Supporting information for this article is available on the WWW under http://www.wiley-vch.de/contents/jc_2452/2008/z700315_s.pdf or from the author. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.